e-learning
resources
Madrid 2019
Wednesday, 02.10.2019
Management of airway diseases in primary care
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Reliever overuse when treatable traits go untreated.
E. Azzi (Sydney, Australia), V. Kritikos (Sydney, Australia), D. Price (Aberdeen, United Kingdom), M. Peters (Sydney, Australia), P. Srour (Sydney, Australia), B. Cvetkovski (Sydney, Australia), S. Bosnic-Anticevich (Sydney, Australia)
Source:
International Congress 2019 – Management of airway diseases in primary care
Session:
Management of airway diseases in primary care
Session type:
Oral Presentation
Number:
5151
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Azzi (Sydney, Australia), V. Kritikos (Sydney, Australia), D. Price (Aberdeen, United Kingdom), M. Peters (Sydney, Australia), P. Srour (Sydney, Australia), B. Cvetkovski (Sydney, Australia), S. Bosnic-Anticevich (Sydney, Australia). Reliever overuse when treatable traits go untreated.. 5151
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Treatable traits as predictors of SABA overuse in the community.
Source: International Congress 2019 – Epidemiology of airway diseases in primary care
Year: 2019
Prevalence of non-pharmacological treatable traits in patients with asthma
Source: Virtual Congress 2020 – New insights into determinants of patient-reported outcomes in chronic respiratory diseases
Year: 2020
Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?
Source: Eur Respir J 2005; 26: 819-828
Year: 2005
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
How can treatable traits be used in severe exacerbations?
Source: Research Seminar 2021 – Unravelling severe exacerbations of COPD – CICERO an ERS CRC
Year: 2021
Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 509s
Year: 2004
Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma
Source: Eur Respir J, 51 (1) 1701688; 10.1183/13993003.01688-2017
Year: 2018
Budesonide/formoterol maintenance and reliever therapy use in elderly asthma patients
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD
Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD
Year: 2020
Predictive factors for asthma control according to ACQ
5
in asthma patients treated with budesonide/formoterol maintenance and reliever therapy. Results from the EuroSMART study
Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management
Year: 2010
Influence of psychiatric disorders in patients treated with Varenicline.
Source: International Congress 2017 – Smoking cessation treatment and e-cigarettes
Year: 2017
Resource utilization and economic impact of switching uncontrolled asthma and exacerbating COPD patients on monotherapy to fixed dose combination treatment in Germany
Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management
Year: 2012
Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: outcomes from the RELIEF study in patients across different severities and age groups
Source: Eur Respir J 2002; 20: Suppl. 38, 45s
Year: 2002
Formoterol turbuhaler is effective and safe as maintenance or maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2002; 20: Suppl. 38, 243s
Year: 2002
Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma
Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Year: 2016
Effect of treatment with tiotropium bromide 18 mcg on asthma control and asthma-related quality of life in patients with asthma-COPD overlap syndrome.
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017
Overall and cardiovascular safety of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in patients with COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Budesonide/formoterol maintenance and reliever therapy compared to conventional best practice in the treatment of persistent asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 616s
Year: 2007
Indacaterol/glycopyrronium (IND/GLY) delays clinically important deterioration (CID) versus salmeterol/fluticasone (SFC) in symptomatic COPD patients: LANTERN/ILLUMINATE pooled analysis
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept